Clinical Trials Browser

Recruiting × Multiple Myeloma × daratumumab × Clear all

NCT04973605 2026-04-16

A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06083922 2026-04-16

A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

Phase 2 Recruiting

Multiple Myeloma

NCT07095452 2026-04-16

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Phase 2/3 Recruiting

Multiple Myeloma

NCT05623020 2026-04-15

MagnetisMM-6

Phase 3 Recruiting

Multiple Myeloma

NCT07107529 2026-04-15

Study for Frail Patients With Newly Diagnosed Multiple Myeloma Treated With Daratumumab With Teclistamab or Talquetamab.

Phase 2 Recruiting

Multiple Myeloma

NCT06182774 2026-04-14

Fixed Duration vs Continuous Anti-CD38 Antibody Therapy Among Transplant Ineligible Older Adults With Newly-Diagnosed Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT06615479 2026-04-14

A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)

Phase 3 Recruiting

Multiple Myeloma, Recurrence

NCT05438043 2026-04-13

A Study of Daratumumab

Phase 3 Recruiting

Multiple Myeloma

NCT05552222 2026-04-13

MajesTEC-7

Phase 3 Recruiting

Multiple Myeloma

NCT06768489 2026-04-13

A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT04566328 2026-04-03

Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

Phase 3 Recruiting

Multiple Myeloma

NCT06918002 2026-04-02

ElLen

Phase 3 Recruiting

Multiple Myeloma

NCT05020236 2026-03-27

MAGNETISMM-5

Phase 3 Recruiting

Multiple Myeloma

NCT06413498 2026-03-27

iMMagine-3

Phase 3 Recruiting

Multiple Myeloma

NCT06932562 2026-03-25

A Study to Learn How Safe and How Well Linvoseltamab Works Compared to Standard Treatment in Adult Patients With Multiple Myeloma Who Are Not Eligible for Transplant

Phase 3 Recruiting

Multiple Myeloma

NCT07452198 2026-03-25

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma

Phase 3 Recruiting

Multiple Myeloma

NCT07391657 2026-03-12

DURGA-4

Phase 3 Recruiting

Multiple Myeloma

NCT05896228 2026-03-11

Iber-KDd

Phase 2 Recruiting

Multiple Myeloma

NCT06953960 2026-02-23

A Study to Assess Adverse Events and Change in Disease Activity of Oral ABBV-453 Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms

NCT06892522 2026-02-17

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving Etentamig (ABBV-383) as an Intravenous (IV) Infusion Alone or in Combination With Oral, IV, Subcutaneous Daratumumab; Lenalidomide; Dexamethasone; Carfilzomib

Phase 1/2 Recruiting

Multiple Myeloma, Neoplasms

NCT06974786 2026-01-23

FASTER

Phase 2 Recruiting

Multiple Myeloma

NCT05137054 2026-01-22

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Patients With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

Phase 1 Recruiting

Multiple Myeloma

NCT05231629 2026-01-09

MASTER-2

Phase 2 Recruiting

Multiple Myeloma

NCT06679101 2026-01-08

DREAMM-10

Phase 3 Recruiting

Multiple Myeloma

NCT04991103 2025-12-31

Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

Phase 2 Recruiting

Amyloidosis, Multiple Myeloma, Neoplasm, Residual

NCT05695508 2025-12-24

HD10/DSMMXX

Phase 2 Recruiting

Multiple Myeloma

NCT06042725 2025-12-24

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT02343042 2025-12-22

STOMP

Phase 1/2 Recruiting

Multiple Myeloma, Recurrence

NCT04068597 2025-12-18

Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Myeloid, Acute, Lymphoma, T-Cell, Peripheral, Hematologic Neoplasms

NCT06827860 2025-12-18

Subcutaneous Talquetamab in Elderly Patients With Multiple Myeloma in Early Relapse

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT06483139 2025-11-19

Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy

GenitourinaryPlasma cell

Multiple Myeloma, Acute Kidney Injury

NCT05363111 2025-10-29

Radioimmunotherapy (111Indium/225Actinium-DOTA-daratumumab) for the Treatment of Relapsed/Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT04176718 2025-10-07

Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT06785415 2025-09-30

Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma

NCT06398457 2025-09-26

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

Phase EARLY_PHASE1 Recruiting

Classical hematologyLymphoidMyeloidOther hematologic neoplasmPlasma cell

Anemia, Aplastic, Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Primary Myelofibrosis

NCT07018050 2025-09-22

Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma, Recurrence

NCT05572229 2025-09-17

IFM2021-01

Phase 2 Recruiting

Multiple Myeloma

NCT06464991 2025-07-20

FUMANBA-03

Phase 3 Recruiting

Multiple Myeloma

NCT06409702 2025-06-12

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Phase 4 Recruiting

Multiple Myeloma

NCT05561387 2025-06-04

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Phase 3 Recruiting

Multiple Myeloma

NCT06119685 2025-06-03

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Phase 1/2 Recruiting

LymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Non-Hodgkin, Multiple Myeloma, Hematologic Neoplasms

NCT06140966 2025-04-16

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2 Recruiting

Multiple Myeloma

NCT06622005 2025-04-16

SX-682 in Combination With Carfilzomib, Daratumumab-Hyaluronidase, and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Phase 1 Recruiting

Multiple Myeloma

NCT04513639 2025-03-20

The Relapse from MRD Negativity As Indication for Treatment (REMNANT) Study

Phase 2/3 Recruiting

Multiple Myeloma

NCT06107738 2025-01-09

IBEX

Phase 2 Recruiting

Multiple Myeloma

NCT06697483 2024-11-25

Risk Stratification and MRD-driven Maintenance for MM After ASCT

Phase NA Recruiting

Multiple Myeloma, Neoplasm, Residual

NCT06187441 2024-08-19

HOVON174MM

Phase 3 Recruiting

Multiple Myeloma

NCT06505369 2024-07-17

TALTEC

Phase 2 Recruiting

Multiple Myeloma

NCT06189833 2024-04-23

TAURUS

Phase 2 Recruiting

Multiple Myeloma

NCT06296121 2024-03-06

DARVIVA

Phase 3 Recruiting

Multiple Myeloma